Short‐term studies with limited numbers of human volunteers also indicate that treatment with native PTHrP(1-36) increased bone formation markers [21–24] and BMD [24], which has driven interest over the past several years in testing PTHrP(1-36) as a potential treatment for osteoporosis. This evidence concerns the gene PTHLH and osteoporosis.